Skip to main content

Towards a Neonatal Vaccine Against Equine Herpesvirus Type 1 (EHV-1)

Principal Investigator: Bettina Wagner

Department of Population Medicine and Diagnostic Sciences
Sponsor: Harry M. Zweig Memorial Fund for Equine Research
Title: Towards a Neonatal Vaccine Against Equine Herpesvirus Type 1 (EHV-1)
Project Amount: $99,314
Project Period: January 2018 to December 2018

DESCRIPTION (provided by applicant): 

Ongoing neurological EHV-1 outbreaks in the US support the increase in morbidity and mortality of disease induced by current EHV-1 strains despite widely used vaccination. EHV-1 is frequently transmitted early in life. Once infected, foals or weanlings remain latently infected and can act as virus reservoirs. Currently, neonatal vaccines to prevent early-in-life infection are unavailable. Neonatal vaccination, in general, is a challenging task because the immune system of young foals reacts differently than that of adult horses. Our preliminary data support the use of a neonatal EHV-1 vaccine targeting memory B-cell activation at birth. A previous trial using our novel neonatal EHV-1 vaccine was supported by the Harry M. Zweig Memorial Fund for Equine Research. The project ended in 2015. The results have recently been published and show proof-of-principle that our neonatal EHV-1 vaccine induces partial protection from disease, a faster and stronger antibody responses against EHV-1 and B-cell memory against the pathogen. Our hypothesis is that vaccination of neonatal foals with IL-4/EHV-1 antigens will induce EHV-1 specific B-cell memory thereby priming the immune system of young foals to an earlier onset of systemic antibody responses after EHV-1 challenge or vaccination Aim 1 is to further improve the concept of neonatal vaccination and to test if IL-4 is essential for neonatal memory B-cell activation. We will analyze if neonatal vaccination with IL-4/EHV-1 antigen primes the immune system of the young vaccinated foal to respond effectively to conventional vaccination at 3 months of age, a time when foals typically mount poor antibody responses to these vaccines. Aim 2 is to evaluate neonatal memory B-cell induction, expression profiles, and possible differences from adult horse memory B-cells. We will also further analyze the influence of IL-4 on EHV-1 specific memory B-cells. The goal of this project is to optimize neonatal vaccination and to achieve full protection from infection using the newly discovered neonatal memory B-cell induction pathway in combination with conventional vaccination early in life. We also aim to further explore the underlying mechanism of neonatal memory B-cell activation. Overall, the project is relevant to prevent transmission of EHV-1 and the development of latency, to achieve protection from disease by increasing immunity the equine population including young foals, and thereby reducing severe neurological and abortion outbreaks in the US.

Share this: